They're partners on the cancer med Erbitux, so why not join forces completely? Bristol-Myers Squibb has offered $4.5 billion for ImClone Systems, a $60-per-share price that represents about a 40 percent premium over the past month's closing prices. Release [1] | Report [2]
Links:
[1] http://www.fiercebiotech.com/press-releases/bristol-myers-squibb-proposes-acquire-imclone-systems-60-00-share-cash
[2] http://money.cnn.com/news/newsfeeds/articles/djf500/200807311010DOWJONESDJONLINE000849_FORTUNE5.htm